Aller au contenu
Trouver un autre spécialiste

Louis-Charles Fortier

Directeur de département, Faculté de médecine et des sciences de la santé
FMSS Dép. de microbiologie et infectiologie

Présentation

Sujet de recherche

Bacterial Infections, Virus (Living Organisms), Microorganisms, Biological and Biochemical Mechanisms

Disciplines de recherche

Microbiology, Virology

Mots-clés

Clostridium difficile, Bacteriophage, Microbiology, Molecular biology, Bioinformatics-genomics, Gene expression, Cell culture, Real-time qRT-PCR, Electron microscopy, Protein expression

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Anglais, Français

Diplômes

(2007). (Post-doctorate, Postdoctorate). Université Laval.

(2001). (Doctorate, Doctorate in Food science). McGill University.

(1996). (Master's Thesis, Master of sciences (M.Sc.) - Masters). Université de Sherbrooke.

(1994). (Bachelor's, Bachelor in Biology (B.Sc.)). Université de Sherbrooke.

Expérience académique

Chair - Department of Microbiology and Infectious Diseases. (2024-). Université de Sherbrooke. Canada.

Chair of the Institutional Animal Care Committee. (2021-). Université de Sherbrooke. Canada.

Director of the Infection - Inflammation Research Theme of the Faculty of Medicine and Health Sciences. (2021-). Université de Sherbrooke. Canada.

Professor (Full). (2017-). Université de Sherbrooke. Canada.

Assistant Head - Research / Department of Microbiology and Infectious Diseases. (2016-2024). Université de Sherbrooke. Canada.

Chair of the faculty of medicine and health sciences animal care committee. (2019-2021). Université de Sherbrooke. Canada.

Associate professor. (2012-2017). Université de Sherbrooke. Canada.

Director of graduate studies in microbiology. (2011-2013). Université de Sherbrooke. Canada.

Assistant professor. (2007-2012). Université de Sherbrooke. Canada.

Postdoctoral fellow. (2004-2007). Université Laval. Canada.

Research professionnal. (2002-2004). Université Laval. Canada.

Professor (Biology). (2000-2002). Cégep de Shawinigan. Canada.

Prix et distinctions

  • (2021) Pharmacology prize / Prix de Pharmacologie (Prize given by the students of Pharmacology to recognize the quality of my teaching). Université de Sherbrooke. (Prize / Award).
  • (2017) Pharmacology prize / Prix de Pharmacologie (Prize given by the students of Pharmacology to recognize the quality of my teaching). Université de Sherbrooke. (Prize / Award).
  • (2016) Junior 2 Salary Award. Fonds de recherche du Québec - Santé (FRQS). (Prize / Award).
  • (2012) Junior 1 Salary Award. Fonds de recherche du Québec - Santé (FRQS). (Prize / Award).
  • (2008) Salary award from the CRCHUS. Centre de recherche clinique Étienne-Le Bel. (Prize / Award).
  • (2007) Postdoc scholarship. CRMUS. (Prize / Award).
  • (2000) PhD Scholarship. Fondation des Gouverneurs - Agriculture Canada (CRDA, St-Hyacinthe). (Prize / Award).
  • (1999) PhD scholarship. FCAR. (Prize / Award).
  • (1998) First prize-oral competition-biotechnology. Institute of Food Technology. (Prize / Award).
  • (1997) PhD Scholarship from the French Government. French Government. (Prize / Award).
  • (1996) M.Sc. Scholarship. Medical Research Council of Canada. (Prize / Award).
  • (1995) M.Sc. Scholarship. Faculty of medicine of the Université de Sherbrooke. (Prize / Award).

Financement

  • Grant. (Under Review). Principal Applicant. Demystifying virus-host interactions in Clostridioides difficile through genetic engineering of bacteriophages and the bacterial S-layer. Canadian Institutes of Health Research (CIHR). Projet. 1 295 000 $. (2004-2029)
  • Grant. (Awarded). Co-applicant. Understanding the interplay between Shp-2 and microbiota in colonic inflammation. Canadian Institutes of Health Research (CIHR). Project. 994 500 $. (2024-2029)
  • Grant. (Awarded). Principal Investigator. Leveraging nanopore sequencing technology of whole Escherichia coli genomes to tailor antibiotherapy and development of phage-based applications to treat urinary tract infections. Sanofi. iDEA-TECH. 149 800 $. (2024-2026)
  • Grant. (Awarded). Principal Applicant. Phage therapy targetting proinflammatory bacteria associated with ulcerative colitis. Temerty Faculty of Medicine - University of Toronto. Bacteriophage Research Accelerator Fund. 50 000 $. (2024-2026)
  • Grant. (Awarded). Co-applicant. Development of an anodised aluminum surface for virucidal, bactericidal and sporicidal applications / Développement d'une surface d'aluminium anodisé pour des applications virucides, bactéricides et sporicides.. Centre québécois de recherche et de développement de l'aluminium (CQRDA). Programme de recherche en partenariat sur l'aluminium. 406 000 $. (2022-2025)
  • Grant. (Awarded). Principal Applicant. Demystifying virus-host interactions in Clostridioides difficile through genetic engineering of bacteriophages and the bacterial S-layer. Canadian Institutes of Health Research (CIHR). Project grant. 100 000 $. (2024-2025)
  • Grant. (Awarded). Principal Investigator. Phage-host interactions in pathogenic and commensal clostridia. Natural Sciences and Engineering Research Council of Canada (NSERC). Discovery. 180 000 $. (2020-2025)
  • Grant. (Awarded). Co-applicant. Epithelial-specific role of SOCS1 in prevention of intestinal inflammation. Canadian Institutes of Health Research (CIHR). Projet. 787 950 $. (2019-2024)
  • Grant. (Awarded). Principal Applicant. Replacement for Anaerobic Workstations. Natural Sciences and Engineering Research Council of Canada (NSERC). Research Tools and Instruments. 145 503 $. (2023-2024)
  • Contract. (Completed). Principal Investigator. Évaluation de la solubilité, de la stabilité, et de l'efficacité antibactérienne du PER-OXY supplémenté de 5 additifs chimiques. Kalium Solutions Inc.. N/A. 14 000 $. (2022-2023)
  • Grant. (Completed). Co-investigator. Development of a synthetic bacterium to fight persistent Gram-positive bacterial infecitons / Développement d’une bactérie synthétique pour lutter contre les infections persistantes à Gram-positif. Centre de recherche du CHUS. Programme de projets structurants. 74 980 $. (2021-2022)
  • Grant. (Completed). Co-investigator. Évaluation de l'efficacité des probiotiques sur les affections post-COVID-19. Canadian Institutes of Health Research (CIHR). Emergig COVID-19 Research Gaps & Priorities - Post COVID-19 condition. 997 273 $. (2021-2022)
  • Grant. (Completed). Co-investigator. Initial vancomycin taper for the prevention of recurrent Clostridium difficile infection. Canadian Institutes of Health Research (CIHR). Projet. 378 676 $. (2019-2021)
  • Grant. (Completed). Principal Investigator. A3S Anodized aluminum: a virucidal surface to fight the COVID-19 pandemic in hospitals, LTCF and public areas / L'Aluminium anodisé A3S : une surface virucide pour lutter contre la pandémie de COVID-19 dans les hôpitaux les CHSLD et les lieux publics. Natural Sciences and Engineering Research Council of Canada (NSERC). Alliance - Covid. 50 000 $. (2020-2021)
  • Contract. (Completed). Principal Investigator. Anodized aluminum-based biocidal surfaces to fight bacterial and viral infections / Surfaces biocides à base d’aluminium anodisé afin de combattre les infections bactériennes et virales. A3 Surfaces Inc.. N/A. 11 830 $. (2020-2021)
  • Contract. (Completed). Co-applicant. Anodized aluminum-based biocidal surface to fight viral infections / Surface biocide à base d’aluminium anodisé afin de combattre les infections virales. Centre québécois de recherche et de développement de l'aluminium (CQRDA). Québec-Innove. 100 000 $. (2020-2020)
  • Grant. (Completed). Principal Investigator. Phage biology and diversity in Clostridium difficile and other commensal clostridia. (2015-2020)
  • Grant. (Completed). Co-applicant. Replacement for Microbial Growth Assay Cluster. Natural Sciences and Engineering Research Council of Canada (NSERC). Research Tools and Instruments. 143 350 $. (2019-2020)
  • Grant. (Completed). Co-applicant. Impact de la concentration en métalloprotéinases 1-2-8-9, d’Enterococcus faecalis, de Pseudomonas aeruginosa et de Klebsiella sur le taux de fuite pancréatique post Whipple.. Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke Inc. (CRCHUS) (Sherbrooke, QC). Programme de financement interne. 25 000 $. (2018-2020)
  • Grant. (Completed). Principal Investigator. Setup and validation of the methodology for virome analysis. / Mise en place et validation de la méthodologie pour l’analyse du virome. Centre de recherche du CHUS. Inflammation-Pain research axis. 16 250 $. (2018-2019)
  • Grant. (Completed). Principal Investigator. Isolation and characterization of Clostridium perfringens lytic phages for veterinary applications in the poultry industry. Natural Sciences and Engineering Research Council of Canada (NSERC). Engage. 25 000 $. (2018-2019)
  • Grant. (Completed). Co-investigator. Développement d'un modèle animal de déclenchement du travail par modification du microbiote intestinal pour une meilleure compréhension des facteurs impliqués dans la prématurité. Fondation des étoiles (La) (Qc). Fondation des étoles. 10 000 $. (2017-2019)
  • Grant. (Completed). Co-investigator. Microbiote intestinal en grossesse et prématurité. Centre de recherche du CHUS. Programme d'Aide au Financement de la Recherche (PAFI). 25 000 $. (2017-2019)
  • Grant. (Completed). Co-applicant. Replacement for Fast Protein Liquid Chromatography System. Natural Sciences and Engineering Research Council of Canada (NSERC). Research Tools and Instruments. 138 000 $. (2018-2019)
  • Grant. (Completed). Co-applicant. Rôle intrinsèque de SOCS1 dans l’épithélium intestinal et l'inflammation. Centre de recherche en inflammation et oncologie digestive de l’UdeS. operating grant. 15 000 $. (2017-2018)
  • Grant. (Completed). Co-investigator. Prophylactic and therapeutic use of chenodeoxycholic acid (CDCA) against Clostridium difficile infection. Centre de recherche du CHUS. PAFI (internal funding program). 25 000 $. (2016-2018)
  • Grant. (Completed). Principal Investigator. Gene expression control by riboswitches: mechanism and role in C. difficile biology and virulence. (2014-2017)
  • Contract. (Completed). Principal Investigator. Therapeutic and prophylactic potential of egg yolk antibodies in the fight against Clostridium difficile infections. Immune Biosolutions inc.. Collaborative research contract. 33 574 $. (2015-2016)
  • Grant. (Completed). Principal Investigator. Anti-Clostridium difficile mechanisms of action of BioK+ probiotics - Étude des mécanismes d’action anti-Clostridium difficile par le probiotique Bio-K+. (2015-2015)
  • Grant. (Completed). Principal Investigator. Phage biology and diversity in Clostridium difficile. (2010-2015)
  • Grant. (Completed). Principal Investigator. Anti-Clostridium difficile mechanisms of action of BioK+ probiotics - Étude des mécanismes d’action anti-Clostridium difficile par le probiotique Bio-K+. (2014-2015)
  • Grant. (Completed). Principal Investigator. Development of specific antibodies targeting the toxins, cell surface proteins, and spores of C. difficile - Développement d’anticorps spécifiques dirigés contre des protéines de surface des bactéries et des spores de C. difficile et ses toxines. (2013-2014)
  • Grant. (Completed). Co-investigator. Development of a new class of antibiotics targeting the guanine riboswitch to fight C. difficile infections - Développement d'une nouvelle classe d'antibiotiques ciblant le riborégulateur guanine pour le traitement des infections à C. difficile. (2012-2014)
  • Grant. (Completed). Co-investigator. Genetic, transcriptional and functional study of c-di-GMP signaling in C. difficile. - Signalisation cellulaire par le c-diGMP chez Clostridium difficile : étude génétique, transcriptionnelle et fonctionnelle. (2010-2013)
  • Grant. (Completed). Principal Investigator. Study on how tigecycline affects the microbiota and bile acid composition of the gut and how it impacts Clostridium difficile lifestyle and susceptibility to Clostridium difficile infection. (2011-2012)
  • Grant. (Completed). Principal Investigator. Role of the post-transcriptional regulator Hfq in virulence of Clostridium difficile - Rôle du régulateur post-transcriptionnel Hfq dans la virulence de Clostridium difficile. (2010-2011)
  • Grant. (Completed). Principal Investigator. Impact of sub-inhibitory concentrations of antibiotics on sporulation of Clostridium difficile. (2009-2011)
  • Grant. (Completed). Principal Investigator. Étude moléculaire des bactériophages infectant Clostridium difficile et développement d'alternatives thérapeutiques pour traiter la diarrhée associée à C. difficile (DACD). (2008-2011)
  • Grant. (Completed). Principal Investigator. Platform for studying virulence factors in anaerobic pathogens and for the development of phage-based therapeutic agents. (2010-2011)
  • Grant. (Completed). Principal Investigator. Mobile genetic elements from Clostridium difficile and development of molecular tools for its genetic manipulation. (2007-2010)
  • Grant. (Completed). Co-investigator. Modulation des profils d'expression génique causée par les toxines du C. difficile dans les cellules de côlon. (2009-2009)
  • Grant. (Completed). Co-investigator. Modulation des profils d'expression génique causée par les toxines du C. difficile dans les cellules de côlon. (2007-2009)
  • Grant. (Completed). Principal Investigator. Development of phage therapy and phage-derived therapeutic molecules to treat Clostridium difficile-associated diarrhea.. (2007-2009)
  • Grant. (Completed). Principal Investigator. Développement de la phagothérapie et de molécules thérapeutiques dérivées des bactériophages pour traiter la diarrhée associée à Clostridium difficile. (2007-2009)
  • Grant. (Completed). Principal Investigator. Étude de la sporulation chez Clostridium difficile et impact sur l'épidémiologie des diarrhées associées à C. difficile (DACD).. (2008-2008)

Publications

Articles de revue

  • Dong Q , Harper S , McSpadden E , Son SS , *Allen MM , Lin H , Smith RC , Metcalfe C , Burgo V , Woodson C , Sundararajan A , Rose A , McMillin M , Moran D , Little J , Mullowney M , Sidebottom AM , Shen A , Fortier LC , Pamer EG. (2024). Clostridioides difficileProtection against disease by a naturally avirulent strain. bioRxiv DOI 10.1101/2024.05. NA. (Published).
  • Wilson J, Fortier LC, Fagan R, Bullough P. (2024). Molecular mechanism of bacteriophage tail contraction-structure of an S-layer-penetrating bacteriophage. Life Science Alliance NA NA. (Submitted).
  • Dong Q , Harper S , McSpadden E , Son SS , Allen MM , Lin H , Smith RC , Metcalfe C , Burgo V , Woodson C , Sundararajan A , Rose A , McMillin M , Moran D , Little J , Mullowney MW , Sidebottom AM , Fortier LC , Shen A , Pamer EG. (2024). Protection against Clostridioides difficile disease by a naturally avirulent strain. Cell host & microbe (Published).
  • *Saunier, M; Fortier, LC; Soutourina, O. (2024). RNA-based regulation in bacteria-phage interactions. Anaerobe 87 102851. (Published).
  • *Jann, J; *Gascon, S; Fradette, J; Auclair-Gilbert, M; Soucy, G; Fortier, LC***; Faucheux, N*** (***Co-corresponding). (2023). Assessment of antibacterial properties and skin irritation potential of anodized aluminum impregnated with various quaternary ammonium. Biomaterials Advances Volume 150 (July 2023), 1-17. (Published).
  • Dong Q, Lin H, *Allen MM, *Garneau JR, Sia JK, Smith RC, Haro F, McMillen T, Pope RL, Metcalfe C, Burgo V, Woodson C, Dylla N, Kohout C, Sundararajan A, Snitkin ES, Young VB, Fortier LC, Kamboj M, Pamer EG. (2023). Clostridioides difficile.Virulence and genomic diversity among clinical isolates of ST1 (BI/NAP1/027). Cell Reports 42 (8), 112861. (Published).
  • *Royer ALM, *Umansky AA, *Allen MM, *Garneau JR, *Ospina-Bedoya M, Kirk JA, Govoni G, Fagan RP, Soutourina O, Fortier LC. (2023). Clostridioides difficileThe S-Layer Protein A (SlpA) serves as a general phage receptor. Microbiology Spectrum Feb 15;e0389422 1-15. (Published).
  • *Umansky AA, Fortier LC. (2023). Clostridioides difficileThe long and sinuous road to phage-based therapy of infections. Frontiers in Medicine 10 1-8. (Published).
  • Granger, MF; Kelly, M; Fortier, LC; Founier, E; Cote-Gravel, J; Malouin, F; Valiquette, L; Lévesque, S. (2023). KlebsiellaChronic diarrhea caused by toxin producer following antibiotic associated hemorrhagic colitis: successful treatment by faecal microbiota transplant. Clinical Infectious Diseases 436 1-4. (Published).
  • Aissou, T; *Jann, J; Faucheux, N; Fortier, LC; Braidy, N; Veilleux, J. (2023). Suspension Plasma Sprayed Copper-graphene Coatings for Improved AntibacterialProperties. Applied Surface Science 639 1-10. (Published).
  • Dong Q, Lin H, Allen MM, Garneau JR, Sia JK, Smith RC, Haro F, McMillen T, Pope RL, Metcalfe C, Burgo V, Woodson C, Dylla N, Kohout C, Sundararajan A, Snitkin ES, Young VB, Fortier LC, Kamboj M, Pamer EG. (2022). Clostridioides difficileVirulence and genomic diversity among clinical isolates of ST1 (BI/NAP1/027). BioRxiv doi: 10.1101/2023.01 1-48. (Published).
  • Valdes, Jennifer Gagné‐Sansfaçon, J; Reyes, V; Armas, A; Marrero, G; Moyo‐Muamba, M; Ramanathan, S; Perreault, N; Ilangumaran, S; Rivard, N; Fortier, LC; Menendez, A. (2022). Defects in the expression of colonic host defense factors associate with barrier dysfunction induced by a high‐fat/high‐cholesterol diet. The Anatomical Record doi:10.1002/ 1-19. (Published).
  • Kautzman, AM; Faida Mobulakani, JM; Marrero Cofino, G; Irmine Quenum, AJ; Armas Cayarga, A; Asselin, C; Fortier, LC; Ilangumaran, S; Menendez, A; Ramanathan, S. (2022). Interleukin 15 in murine models of colitis. The Anatomical Record doi:10.1002/a 1-20. (Published).
  • *Smith-Peter, E; *Lalonde Séguin, D; *St-Pierre, E; *Sekulovic, O; Jeanneau, S; Tremblay-Tétreault, C; Lamontagne, A-M; Jacques, P-E; Lafontaine, D A; Fortier, L-C. (2021). Clostridioides difficileInactivation of the riboswitch-controlled GMP synthase GuaA in is associated with severe growth defects and poor infectivity ina mouse model of infection. RNA Biology 18 (2), 699-710. (Published).
  • Heuler, J; Fortier, LC; Sun, X. (2021). Clostridioides difficile Phage Biology and Application. FEMS Microbiology Reviews 45 (5), fuab012. DOI. (Published).
  • *Garneau, JR; Legrand, V; Marbouty, M; Press, MO; Vik, DR; Fortier, LC; Sullivan, MB; Bikard, D; Monot, M. (2021). High-throughput identification of viral termini and packaging mechanisms in virome datasets using PhageTermVirome. Scientific Reports 11 (1), 18319. (Published).
  • Bouchard, ME; Rousseau, E; Fortier, LC; Girard, I. (2021). Pathophysiology of Vaginal Erosions in Women Using Pessary: a pilot study examining vaginal microbiota. J Obstet Gynaecol Can S1701-2163 (21), 00347-9. DOI. (Published).
  • *Jann ,J; Drevelle, O; Chen, XG; Auclair-Gilbert, M; Soucy, G; Faucheux, N; Fortier, LC. (2021). Rapid antibacterial activity of anodized aluminum-based materials impregnated with quaternary ammonium compounds for high-touch surfaces to limit transmission of pathogenic bacteria. RSC Advances 11 38172–38188. (Published).
  • Peltier, J; Hamiot, A; *Garneau, JR; Boudry, P; Maikova, A; Hajnsdorf, E; Fortier, LC; Dupuy, B; Soutourina, O. (2020). Clostridioides difficileType I toxin-antitoxin systems contribute to the maintenance of mobile genetic elements in. Communications Biology 3 (1), 718. (Published).
  • Selle K, Fletcher J, Tuson H, Schmitt D, McMillan L, Vridhambal G, Rivera A, Montgomery S, Fortier LC, Barrangou R, Theriot C, Ousterout D. (2020). In vivo targeting of using phage-delivered CRISPR-Cas3 antimicrobials. mBio 11 (2), e00019-20. (Published).
  • *Garneau JR, Abou Chakraa CN, Fortier LC, Labbé AC, Simor AE, Gold W, Muller M, McGeer A, Powis J, Katz K, Pépin J and L Valiquette. (2019). Clostridioidis difficileMultilocus Variable-Number Tandem-Repeat Analysisof Clustersin Ribotype 027 Isolates and Lack of Association with Clinical Outcomes. Journal of Clinical Microbiology 26 (57), e01724-18. (Published).
  • Fortier, LC. (2018). Clostridioides (Clostridium) difficileBacteriophages contribute to shaping species. Frontiers in Microbiology (commissioned article) 9 2033. (Published).
  • Yan LH, Le Roux A, Boyapelly K, Lamontagne AM, Archambault MA, Picard-Jean F, *Lalonde-Seguin D, *St-Pierre E, Najmanovich RJ, Fortier LC, Lafontaine D, Marsault É. (2018). Clostridioides difficilePurine analogs targeting the guanine riboswitch as potential antibiotics against . European Journal of Medicinal Chemistry 143 755-757. (Published).
  • Carignan A (Corr. author), Fortier LC. (2018). Discovery of keyicin, a new antibiotic: it takes two to tango. Médecine/Sciences 34 (5), 377-379. (Published).
  • *Garneau J, *Sekulovic O, Dupuy B, Soutourina O, Monot M, Fortier LC. (2018). High Prevalence and Genetic Diversity of Large phiCD211 (phiCDIF1296T)-Like Prophages in Clostridioides difficile. Applied and Environmental Microbiology 84 (3), e02164-17. (Published).
  • Allard M, Bergeron J, Baharnoori M, Srivastava L, Fortier LC, Poyart C, Sébire G. (2017). A sexually dichotomous, autistic-like phenotype is induced by Group B Streptococcus maternofetal immune activation. Autism Research 10 (2), 233-245. (Published).
  • Tremblay S,Côté NML*, Grenier G, Duclos-Lasnier G, Fortier LC, Ilangumaran S, Menendez A. (2017). Ileal antimicrobial peptide expression is dysregulated in old age. Immunity & Aging 14 (19), 1-5. (Published).
  • *Garneau JR, Depardieu F, Fortier LC, Bikard D, Monot M. (2017). PhageTerm: a tool for fast and accurate determination of phage termini and packaging mechanism using next-generation sequencing data. Scientific Reports 7 1-10. (Published).
  • Bergeron J, Gerges N, Guiraut C, Djordje Grbic, Allard MJ, Fortier LC, Vaillancourt C, Sébire G. (2016). Activation of the IL-1?/CXCL1/MMP-10 axis in chorioamnionitis induced by inactivated Group B Streptococcus. Placenta 47 116-123. (Published).
  • Abou Chakra CN, McGeer A, Labbé AC, Simor AE, Gold WL, Muller MP, Powis J, Katz K, *Garneau JR, Fortier LC, Pépin J, Cadarette SM, Valiquette L. (2015). Clostridium difficileFactors Associated With Complications of Infection in a Multicenter Prospective Cohort. Clinical Infectious Diseases 61 (12), 1781-1788. (Published).
  • Boudry P, Semenova E, Monot M, Datsenko KA, Lopatina A, *Sekulovic O, *Ospina-Bedoya M, Fortier LC, Severinov K, Dupuy B, Soutourina O. (2015). Clostridium difficileFunction of the CRISPR-Cas System of the Human Pathogen . mBio 6 (5), e01112-15. (Published).
  • *Sekulovic O, *Ospina Bedoya M, Fivian-Hughes AS, Fariweather NF, Fortier LC. (2015). Clostridium difficileThe Cell Wall Protein CwpV Confers Phase-Variable Phage Resistance. Molecular Microbiology 98 (2), 329-342. (Published).
  • Bordeleau E, Purcell EB, Lafontaine DA, Fortier LC, Tamayo R, Burrus V. (2015). Cyclic-di-GMP riboswitch-regulated type IV pili contribute to aggregation of Clostridium difficile. Journal of Bacteriology 197 (5), 819-832. (Published).
  • Bergeron J, Deslauriers J, Grignon S, Fortier LC, Lepage M, Stroh T, Poyart C, Sébire G. (2015). Exposition to group B streptococcal maternalinflammation: White matter injury and autistic-like behavior predominantlyaffecting male rat offspring. Int J Dev Neurosci 47 (A), 47-48. (Published).
  • *Sekulovic O, Fortier LC. (2015). Global transcriptional response of Clostridium difficile carrying the ?CD38-2 prophage. Applied and Environmental Microbiology 81 (4), 1364-1374. (Published).
  • Allard MJ, Bergeron J, Grbic D, Fortier LC, Poyart C, Sébire G. (2015). StreptococcusGroup B infection during gestation induces gender specific neurodevelopmentalimpairments. Int J Dev Neurosci 61 (12), 86. (Published).
  • *Sekulovic O, *Garneau JR, *Néron A, Fortier LC. (2014). Characterization of Temperate Phages Infecting Clostridium difficile Isolates from Human and Animal Origin. Applied and environmental microbiology 80 (8), 2555-2563. (Published).
  • *Garneau JR, Valiquette L, Fortier LC. (2014). Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC infectious diseases 14 (1), 29. (Published).
  • Fortier LC, *Sekulovic O. (2013). Importance of prophages to evolution and virulence of bacterial pathogens. Virulence 4 (5), 354-365. (Published).
  • Bergeron JD , Deslauriers J , Grignon S , Fortier LC , Lepage M , Stroh T , Poyart C , Sébire G. (2013). White matter injury and autistic-like behavior predominantly affecting male rat offspring exposed to group B streptococcal maternal inflammation. Developmental neuroscience 35 (6), 504-515. (Published).
  • *Meessen-Pinard M , *Sekulovic O , Fortier LC. (2012). Evidence of in vivo prophage induction during Clostridium difficile infection. Applied and environmental microbiology 78 (21), 7662-7670. (Published).
  • Gebhart D , Williams SR , Bishop-Lilly KA , Govoni GR , Willner KM , Butani A , Sozhamannan S , Martin D , Fortier LC , Scholl D. (2012). Novel high-molecular-weight, R-type bacteriocins of Clostridium difficile. Journal of bacteriology 194 (22), 6240-6247. (Published).
  • *Sirard S , Valiquette L , Fortier LC. (2011). Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. Journal of clinical microbiology 49 (12), 4040-4046. (Published).
  • *Sekulovic O , *Meessen-Pinard M , Fortier LC. (2011). Prophage-stimulated toxin production in Clostridium difficile NAP1/027 lysogens. Journal of bacteriology 193 (11), 2726-2734. (Published).
  • Bordeleau E , Fortier LC , Malouin F , Burrus V. (2011). c-di-GMP turn-over in Clostridium difficile is controlled by a plethora of diguanylate cyclases and phosphodiesterases. PLoS genetics 7 (3), e1002039. (Published).
  • Gonzales M , Pepin J , Frost EH , Carrier JC , Sirard S , Fortier LC , Valiquette L. (2010). Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC infectious diseases 10 (Published).
  • Mulhbacher J , Brouillette E , Allard M , Fortier LC , Malouin F , Lafontaine DA. (2010). Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways. PLoS pathogens 6 (4), e1000865. (Published).
  • Matte I , Lane D , Côté E , Asselin AE , Fortier LC , Asselin C , Piché A. (2009). Antiapoptotic proteins Bcl-2 and Bcl-XL inhibit Clostridium difficile toxin A-induced cell death in human epithelial cells. Infection and immunity 77 (12), (Published).
  • Haaber J , Moineau S , Fortier LC , Hammer K. (2008). AbiV, a novel antiphage abortive infection mechanism on the chromosome of Lactococcus lactis subsp. cremoris MG1363. Applied and environmental microbiology 74 (21), (Published).
  • Fortier LC , Moineau S. (2007). Morphological and genetic diversity of temperate phages in Clostridium difficile. Applied and environmental microbiology 73 (22), (Published).
  • Fortier LC , Bransi A , Moineau S. (2006). Genome sequence and global gene expression of Q54, a new phage species linking the 936 and c2 phage species of Lactococcus lactis. Journal of bacteriology 188 (17), (Published).
  • Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C. (2006). The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug metabolism and disposition: the biological fate of chemicals 34 (7), (Published).
  • Fortier LC , Bouchard JD , Moineau S. (2005). Expression and site-directed mutagenesis of the lactococcal abortive phage infection protein AbiK. Journal of bacteriology 187 (11), (Published).
  • Girard H , Thibaudeau J , Court MH , Fortier LC , Villeneuve L , Caron P , Hao Q , von Moltke LL , Greenblatt DJ , Guillemette C. (2005). UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology (Baltimore, Md.) 42 (2), (Published).
  • Girard H , Court MH , Bernard O , Fortier LC , Villeneuve L , Hao Q , Greenblatt DJ , von Moltke LL , Perussed L , Guillemette C. (2004). Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14 (8), (Published).
  • Fortier LC , Tourdot-Maréchal R , Diviès C , Lee BH , Guzzo J. (2003). Induction of Oenococcus oeni H+-ATPase activity and mRNA transcription under acidic conditions. FEMS microbiology letters 222 (2), (Published).
  • Villeneuve L , Girard H , Fortier LC , Gagné JF , Guillemette C. (2003). Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. The Journal of pharmacology and experimental therapeutics 307 (1), (Published).
  • Guzzo J , Jobin MP , Delmas F , Fortier LC , Garmyn D , Tourdot-Maréchal R , Lee B , Diviès C. (2000). Regulation of stress response in Oenococcus oeni as a function of environmental changes and growth phase. International journal of food microbiology 55 (1-3), (Published).
  • Tourdot-Maréchal R , Fortier LC , Guzzo J , Lee B , Diviès C. (1999). Acid sensitivity of neomycin-resistant mutants of Oenococcus oeni: a relationship between reduction of ATPase activity and lack of malolactic activity. FEMS microbiology letters 178 (2), (Published).
  • Fortier LC , Delbecchi L , Bourgaux-Ramoisy D , Bourgaux P. (1998). Rescue of polyomavirus DNA after co-transfection of recombinant plasmids with viral DNA fragments. Biochimica et biophysica acta 1395 (1), (Published).

Chapitres de livre

  • Fortier, LC. (2017). The contribution of bacteriophages to the biology and virulence of pathogenic clostridia. Gadd GM, Sariaslani S. Advances in Applied Microbiology (Commissioned chapter) (101, 1-10). Netherlands : Elsevier. (Published).
  • *Sekulovic O, Fortier LC. (2016). Characterization of functional prophages in Clostridium difficile. Adam Roberts and Peter Mullany. Methods in Molecular Biology - Clostridium difficile. (Commissioned chapter) (476, 143-65). United Kingdom : Humana Press. (Published).
  • Fortier LC, Moineau S. (2009). Phage production and maintenance of stocks, including expected stock lifetimes. Clokie MRJ and Kropinski AM. Methods in Molecular biology (501, 203-219). United States of America : Clokie MRJ and AM Kropinski. (Published).

Articles de conférence

  • *Umansky, AA; *Garneau, JR; Peltier, J; *Royer, ALM; Fortier, LC. (2024). ** Selected for an oral presentation by the organizing committeeGenetic Engineering of Clostridioides difficle Phages. Viruses of Microbes. (Published).
  • *Chénard, A; *Tuytschaevers, S; *Champoux, A; Rinard, N; Fortier LC. (2024). ** Selected for an oral presentation by the selection committee.Développement d’une méthode de modulation du microbiote intestinal lors de la colite induite par la perte d’expression de shp-2 intestinal. Club de Recherche Clinique du Québec (CRCQ). (Published).
  • Royer, ALM; Umansky, AA; Fagan, RP; Soutourina, O; Fortier, LC. (2024). C. difficileExploring the interaction specificity of phages. Viruses of Microbes. (Published).
  • *Royer A, *Umansky A, Fagan RP, Soutourina O, Fortier LC. (2023). ClostridioidesUnravelling the interaction specificity of bacteriophages. 13th International Conference on the Molecular Biology and Pathogenesis of Clostridia (ClostPath). (Published).
  • *Umansky A, *Garneau J, Peltier J, *Royer A, Fortier LC. (2023). Clostridioides difficileGenetic engineering of bacteriophages. 13th International Conference on the Molecular Biology and Pathogenesis of Clostridia (ClostPath). (Published).
  • *Umansky A, Fortier LC. (2023). Clostridioides difficile Modification génétique des bactériophages de. Congrès Bactériologie intégrative: Symbiose - Pathogenèse - BiSP. (Published).
  • *Saunier M, Kreis V, Fortier LC, Soutourina O. (2023). Clostridioides difficileStudy of a potential antiphage system of the "abortive infection" type regulated by a non-coding RNA in. 13th International Conference on the Molecular Biology and Pathogenesis of Clostridia (ClostPath). (Published).
  • *Royer ALM, *Allen MM, *Umansky AA, *Garneau JR, *Ospina-Bedoya M, Kirk JA, Govoni G, Fagan RP, Fortier LC. (2022). Clostridioides difficileCaractérisation de la spécificité d’infection des phages de. ACFAS. (Published).
  • *Royer ALM, *Allen MM, *Umansky AA, *Garneau JR, *Ospina-Bedoya M, Kirk JA, Govoni G, Fagan RP, Fortier LC. (2022). Clostridioides difficileSpecificity of phage-host interactions in. 71st Annual Conference of the Canadian Society of Microbiologists (CSM 2022). (Accepted).
  • *Chénard A, Ben Lagha A, *Garneau JR, Rivard N, Fortier LC. (2021). Modulation du virobiote intestinal lors de la colite induite par la perte d’expression de la phosphatase Shp-2 dans l’épithélium intestinal. Journée Phare. (Published).
  • *Allen, MA; *Sbaghdi, T; *Garneau, JR; Gaucher, ML; Labrie, SJ; Fortier, LC. (2020). Clostridium perfringensIsolation and characterization of lytic phages infecting for veterinary applications in the avian industry. Phage Canada virtual meeting (National event). Canada, (Accepted).
  • Bouchard ME, Fortier LC, Rousseau E, Girard I. (2019). ***This poster won the first prize***Pathophysiologie des ulcérations chez les patientes porteuses de pessaire. Annual meeting of the association of gynecologists and obstetricians of Quebec (AOGQ) (Provincial event). (Published).
  • *Garneau JR, Peltier J, Hamiot A, Tremblay Y, *Turcotte A, Dupuy B, Valiquette L, Monot M, Fortier LC. (2019). Clostridioides difficileImpacts of the phi027 prophage on the biology and virulence of the epidemic strain ribotype 027. Annual meeting of the Canadian Society of Microbiologists (CSM) (International event). (Published).
  • *Jann J, Drevelle O, Dumont M, Bernier JL, Agbe H, Sarkar DK, Chen XG, Soucy G, Fortier LC, and Faucheux N. (2019). Development of biocidal surface technology based on anodized aluminum designed to fight nosocomial infections. 69th Canadian Chemical Engineering Conference (National event). (Accepted).
  • Bouchard ME, Fortier LC, Rousseau E, Girard I. (2019). Pathophysiology of ulcerations in women using pessary; experimental study. International Urogynecological Association (IUGA)/American Urogynecologic Society (AUGS) joint annual meeting (International event). (Accepted).
  • Fortier LC. (2018). C. difficile phages. 6th International Clostridium dificile Symposium (ICDS) (International event). (Submitted).
  • *Allen MM, *Ospina-Bedoya M, Kirk J, Fagan R, Govoni G, Fortier LC. (2018). Clostridium difficileThe surface layer proteinA (SlpA) serves as a general receptor for bacteriophage infection. 68th annual conference of the Canadian Society of Microbiologists (CSM) (International event). (Submitted).
  • Pasquier JC, Lewin A, *St-Pierre E, Gillet V, Fortier LC. (2017). Fecal transplants disturb length of pregnancy in a mouse model. 37th Annual pregnancy meeting of the Society of Maternal-Fetal Medicine (SMFM) (Jan 23-28). Las Vegas, NV, USA. (Published).
  • *Garneau JR, Depardieu F, Fortier LC, Bikard D, Monot M. (2017). PhageTerm: a Fast and User-friendly Software to Determine Bacteriophage Termini and Packaging Mode using randomly fragmented NGS data. Centennial Celebration of Bacteriophage Research (April 24-26). Institut Pasteur, Paris, France. (Accepted).
  • *Garneau JR, Depardieu F, Fortier LC, Bikard D, Monot M. (2017). Phageterm: a fast and user-friendly software todetermine bacteriophage termini and packaging mode using randomly fragmented NGSdata. Annual meeting of the Canadian Society for Microbiologists (CSM) (June 20-23) Waterloo, ON, Canada. (Accepted).
  • Allard MJ, Guiraut C, Descoteaux M, Tremblay L, Lepage M, Fortier LC, Sébire G. (2017). StreptococcusPlacental group B infection: sex specific inflammatory response andautistic-like traits in male offspring. Meeting of the International Society for Autism Research (INSAR/IMFAR) (May 10-13). San Francisco, CA, USA. (Accepted).
  • *Larocque M, Fortier LC, Najmanovich R. (2016). Clostridium difficileIntegrative approach in drugs discovery pipeline applied to . ISMB/SigBio joint meetings, Orlando, FL, USA July 8-12. (Published).
  • *Garneau JR, Monot M, Valiquette L, Fortier LC. (2016). Clostridium difficileProphage elements as a significant source of genetic diversity among epidemic R027 clinical isolates of . Annual meeting of the Canadian Society for Microbiologists (CSM). (Published).
  • *Ospina-Bedoya M, Fagan R, Govoni G, Fortier LC. (2016). Clostridium difficileRole of the Surface Layer Protein A in bacteriophage infection. Annual meeting of the Canadian Society for Microbiologists (CSM). (Published).
  • Abou Chakra CN, McGeer A, Labbé AC, Simor AE, Gold W, Muller MP, Devlin R, Powis J, Katz K, *Garneau JR, Fortier LC, Pépin J, Valiquette L. (2015). Clostridium difficileIndependent Risk Factors for Recurrence of Infection: ACanadian Multicenter Prospective Cohort. IDWeek. (Published).
  • *Garneau JR, Abou Chakra CN, Labbé AC, McGeer A, Pépin J, Valiquette L, Fortier LC. (2015). ClostridiumdifficileRelationship between MLVA genetic types andclinical outcomes following infection by ribotype 027. 5th ICDS meeting. (Published).
  • *Michaud A, *Smith-Peter E, Lafontaine DA, Fortier LC. (2015). Clostridium difficileThe riboswitch-controlled GMP synthase GuaA is important for survival andvirulence of and in a mouse model ofinfection. Annual meeting of the RiboClub. (Published).
  • *Sekulovic O, Fortier LC. (2014). Clostridium difficileA first glance atphage-host interactions in . General meeting of the American Society for Microbiology (ASM. (Published).
  • *Garneau JR, Abou Chakra CN, Fortier LC, Labbé AC, McGeer A, Pépin J, Valiquette L. (2014). Clostridium difficileAnalyse de l'impact des types génétiques bactériens MLVA sur les issues cliniques d'infection par ribotype 027. Annual meeting of the Association des Médecins Microbiologistes infectiologues du Québec - AMMIQ. (Published).
  • Bordeleau E, Purcell EB, Paquette-D’Avignon M, Lafontaine DA, Fortier LC, Tamayo R, Burrus V. (2014). Cyclic-di-GMP signaling and type IV pili-mediated aggregation in Clostridium difficile. 114th General meeting of the America Society for Microbiology (ASM). (Published).
  • Allard MJ, Bergeron J, Grbic D, Fortier LC, Poyart C, Sébire G. (2014). StreptococcusGroup B infection during gestation induces gender specific neurodevelopmentalimpairments. Joint Meeting of the 20th Biennial Meeting of the International Society for Developmental Neuroscience and the 5th Annual NeuroDevNet Brain Development Conference (ISDN, NeuroDevNet 2014). (Published).
  • Allard MJ, Bergeron J, Fortier LC, Poyart C, Sébire G. (2014). StreptococcusGroup B infection during gestation leads to gender specific neurodevelopmental andbehavioural impairments. Annual Meeting of the Society for Neuroscience. (Published).
  • *Garneau JR, *Sekulovic O, *Néron A, Fortier LC. (2014). Temperate phages of Clostridium difficile isolated from farm animals. 114th General meeting of the America Society for Microbiology (ASM). (Published).
  • *Sekulovic O, Fortier LC. (2013). A First Glance at Phage-Host Interactions in Clostridium difficile. 8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia – ClosPath. (Published).
  • Bergeron J, Brochu ME, Deslauriers J, Grignon S, Fortier LC, Sébire G. (2013). Gestational exposure to inactivated Group B Streptococcus induced gender-dependent brain damage and autistic features in offspring. Pediatric Academic Societies/Eastern Society for Pediatric Research Annual Meeting. (Published).
  • Bergeron J, Allard MJ, Deslauriers J, Grignon S, Sarret P, Fortier LC, Poyart C, Sébire G. (2013). Group B Streptococcus inflammatory response induced during gestation recapitulates perinatal injuries and subsequent behavioral impairments affecting premature human newborn such as autistic features in male offspring. Meeting of the Society for Neuroscience. (Published).
  • Abou Chakra CN, Labbé AC, McGeer A, Simor A, Gold W, Devlin R, Katz K, Powis J, Fortier LC, Muller MP, *Garneau JR, Pepin J, Valiquette L. (2013). Risk factors for complications of Clostridium difficile Infection in a prospective multicentre cohort. IDWeek. (Published).
  • Gebhart D, Scholl D, Vacin C, Fortier LC, Williams S, Govoni G. (2012). Diffocins: novel, high-molecular weight bacteriocins highly specific for Clostridium difficile. 4th International Conference on Clostridium difficile (4th ICDS). (Published).
  • St-Pierre E, Lalonde Séguin D, Burrus V, Fortier LC. (2012). Inactivation of chemotaxis-associated genes increases flagellar motility in Clostridium difficile. 4th International Conference on Clostridium difficile (4th ICDS). (Published).
  • Garneau JR, Valiquette L, Fortier LC. (2012). La sporulation de Clostridium difficile est inhibée par des concentrations sous-inhibitrices de tigecycline et de piperacillin-tazobactam in vitro. Annual scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Published).
  • St-Pierre E, Pépin ME, Burrus V, Fortier LC. (2012). Rôle de la mobilité et du chimiotactisme dans la virulence de Clostridium difficile. Annual scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Published).
  • Kelly M, Fortier LC. (2011). Antimicrobial activity of beta-bio 45% hops extract against Clostridium difficile NAP1/027 (Abstract #32532). 49th Annual Meeting of the Infectious Diseases Society of America - IDSA. (Published).
  • Sirard S, Valiquette L, Fortier LC. (2011). Can the clinical outcomes associated with Clostridium difficile Infections (CDI) be predicted by bacterial genotype and phenotypes?. Annual meeting of the Association des Médecins Microbiologistes infectiologues - AMMI. (Published).
  • Bergeron J, Girard S, Brochu ME, Fortier LC, Sébire G. (2011). Implication du Streptocoque de groupe B dans les lésions cérébrales périnatales. Annual scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Published).
  • Gebhart D, Williams S, Fortier LC, Govoni G, Scholl D. (2011). Phage tail-like bacteriocins of Clostridium difficile. 7th International Conference on the Molecular Biology and Pathogenesis of the Clostridia (ClosPath). (Published).
  • Bergeron J, Girard S, Brochu ME, Fortier LC, Sebire G. (2011). Role of gestational inflammation induced by group B streptococcus in perinatal brain lesions and subsequent cerebral palsy. 40th Annual Meeting of the Child Neurology Society. (Published).
  • Néron A, Sekulovic O, Fortier LC. (2010). Diversité et biologie des bacteriophages de Clostridium difficile isolés de souches animales. Annual Pharmacology meeting, faculty of medicine of the Université de Sherbrooke. (Published).
  • Pinard MM, Fortier LC. (2010). In vivo prophage induction in patients infected by Clostridium difficile. Viruses of Microbes meeting. (Published).
  • Bergeron J, Girard S, Brochu ME, Fortier LC, Sébire G. (2010). Mise au point d’un modèle animal de paralysie cérébrale par exposition gestationnelle au Streptocoque de groupe B inactivé. Annual meeting of Pediatrics, Sherbrooke hospital center (CHUS). (Published).
  • Sirard S, Valiquette L, Fortier LC. (2010). Peut-on prédire la sévérité des infections à C. difficile (ICD) en se basant sur le phénotype et le génotype bactériens ?. 39th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Published).
  • Sirard, S, Valiquette, L, Fortier LC. (2010). Peut-on prédire la sévérité des infections à C. difficile (ICD) en se basant sur l’analyse génotypique et phénotypique des souches bactériennes?. 78th Meeting of the ACFAS. (Published).
  • Sekulovic O, Fortier LC. (2010). Prophage-enhanced toxin production in Clostridium difficile NAP1/027 lysogens. Viruses of Microbes meeting. (Published).
  • Sirard S, Valiquette L, Fortier LC. (2010). Prédire la sévérité des infections à C. difficile : plus difficile qu’il n’y paraît !. Annual research meeting of the Université de Sherbrooke. (Published).
  • Fortier LC, Matte I, Côté É, Asselin A-É, Asselin C, Piché A. (2009). Anti-apoptotic proteins Bcl-2/Bcl-XL protect from Clostridium difficile toxin A-induced cell death. 26th International Congress of Chemotherapy and Infection (ICC). (Published).
  • Sekulovic O, Fortier LC. (2009). Impact des prophages sur la biologie de Clostridium difficile. 38th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Published).
  • Pinard MM, Fortier LC. (2009). La phagothérapie contre Clostridium difficile : une réalité ?. 38th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Published).
  • Mauler S, Pinard MM, Sekulovic O, Fortier LC. (2009). Les bactériophages contre C. difficile : réalité ou utopie ?. Annual research meeting of the Université de Sherbrooke. (Published).
  • Haaber J, Moineau S, Fortier LC, Hammer K. (2008). AbiV, a novel abortive phage infection mechanism on the chromosome of Lactococcus lactis subsp. cremoris MG1363. 9th Symposium on Lactic Acid Bacteria. (Published).
  • Pinard MM, Sekulovic O, Fortier LC. (2008). Les phages de Clostridium difficile : rôle dans la virulence et potentiel thérapeutique. 37th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Published).
  • Pinard MM, Sekulovic O, Fortier LC. (2008). Les phages de Clostridium difficile : rôle dans la virulence et potentiel thérapeutique. Annual research meeting of the Université de Sherbrooke. (Published).
  • Mauler S, Fortier LC. (2008). Potentiel thérapeutique des endolysines pour prévenir ou traiter les infections à Clostridium difficile. 37th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Published).
  • Mauler S, Fortier LC. (2008). Potentiel thérapeutique des endolysines pour prévenir ou traiter les infections à Clostridium difficile. Annual research meeting of the Université de Sherbrooke. (Published).
  • *Umansky, AA; *Royer, ALM; *Garneau, JR; Peltier, J; Fagan, RP; Soutourina, O; Fortier, LC. C. difficileSusceptibility to phage infection in is driven by specific interaction between the S-layer protein SlpA and phage receptor binding proteins. 8th International Clostridium difficile Symposium. (Published).
  • Rivard, N; Langlois, MJ; Chabot, V; Rodrigue, S; Fortier, LC. Comprendre l'interaction entre Shp-2 et le microbiote dans l'inflammation intestinale. Signalisation Québec. (Published).

Propriétés intellectuelles

Patents

  • GAUDREAU S, CLOUTIER M, FORTIER LC, LEDUC F, Tremblay M, VERONNEAU S, GBRIC D, LARRIVEE JF. (2016). C. difficile antibodies directed thereto, and target for the treatment of humans and other animals intoxicated with at least one bacterial toxin A and/or B. 62118450. Canada. (Granted/Issued).

Autres contributions

Cours enseignés

  • Virology / Virologie. VIR 500. (2022-01-01).(2CR).
  • Virology lab / Travaux pratiques en virologie. VIR 515. (2020-09-01).(1CR).
  • Microbiologie en pharmacologie. MCB103. (2016-09-01).
  • Le microbiome dans la physiologie, l'immunologie et le métabolisme de l'hôte. MCR717. (2016-01-01).

Gestion d'évènements

  • Co-chair. (2019) 69th annual meeting of the Canadian Society of Microbiologists (CSM). (Conference).
  • Co-organizer. (2019) Annual scientific retreat of the Inflammation & Pain research axis of the CHUS research center. Club de Golf de Sherbrooke, (May 8) Sherbrooke, QC, CA. (Conference).

Activités de collaboration internationale

  • Principal investigator and Collaborator. France. Clostridium difficileMy team collaborates with a group at the Institut Pasteur in Paris, Marc Monot and Bruno Dupuy, and from the Université Paris Saclay, with Olga Soutourina. The research project is on CRISPRs in , as well as phages of . Three of my current/former students have been involved in the project so far: Ognjen Sekulovic (PhD completed in 2015), Maicol Ospina Bedoya (MSc completed in 2017), and Julian R. Garneau, currently PhD candidate in my lab and co-supervised by Dr. Marc Monot from the Institut Pasteur. This is a long-term collaboration.
  • Principal investigator and Collaborator. United Kingdom. Clostridioides difficileI collaborate with Pr. Robert P. Fagan from the University of Sheffield (UK). Our goal is to study the interaction of phages with the cell surface of . The Fagan group is involved in Cryo-EM work with some of our phages. They also share strains and mutants with us, allowing us to perform various phage assays and phage-host interactions studies in . The aim is to get pictures of phage particles interacting with their host receptor and to characterize the molecular interactions between phages and surface layer proteins on the surface of.
  • Collaborator. United States of America. C. difficileI have collaborated with the private company AvidBiotics in South San Francisco (CA, USA). The subject is phages and phage tail-like particles that I had identified and described earlier in a paper (Fortier and Moineau, AEM 2007). We published together in 2012 (Gebhart et al, JBacteriol 2012). I also obtained a mutant strain from them and we are currently completing a manuscript that we expect to submit in fall 2018.
  • Principal investigator. United Kingdom. We started to collaborate with the group of Neil Fairweather on the study of the cell wall associated protein CwpV in C. difficile. They shared with us various constructions of CwpV and antibodies and we shared our recent research results with them. They will be co-authors of a publication to be submitted soon on the antiphage activity of CwpV (Sekulovic et al, in preparation). Our objective is to work together to try to clarify the biological function of CwpV. We also collaborate with Robert Fagan from the university of Sheffield, UK, on the identificaiton of phage receptors in C. difficile. Dr Fagan shares with us bacterial strains, mutants, and plasmid constructions of different slpA alleles. A manuscript will be submitted in fall 2018 with Dr Fagan as a co-author.

Présentations

  • Fortier LC. (2024). Engineering bacteriophage-based therapeutics to fight multidrug resistant bacteria. Invited talk by Sanofi Vaccines (Virtual presentation on Zoom with Sanofi people from Europe, USA and Canada divisions). Canada
  • Fortier LC. (2022). Phagothérapie des infections à Clostridioides difficile: état des lieux. ACFAS annual meeting (International). Virtual, Canada
  • Fortier LC. (2021). Importance du microbiome et du virome en obstétrique/gynécologie. Grand Round seminar series (presented to medical doctors and clinical researchers). Sherbrooke, Canada
  • *Allen, MM (Speaker); *Sbaghdi, T; *Garneau, JR; Gaucher, ML; Labrie, SJ; Fortier, LC. (2020). Isolation and characterization of lytic phages infecting Clostridium perfringens for veterinary applications in the avian industry. Phage Canada (virtual meeting - national). Canada
  • *Jann J, Drevelle O, Dumont M, Bernier JL, Agbe H, Sarkar DK, Chen XG, Soucy G, Fortier LC, Faucheux N. (2019). Development of biocidal surface technology based on anodized aluminum designed to fight nosocomial infections. ***Selected by the organizing committee for an oral presentation. 69th Canadian Chemical Engineering Conference. Halifax, Canada
  • *Garneau JR, Peltier J, Hamiot A, Tremblay Y, Turcotte A, Dupuy B, Valiquette L, Monot M, Fortier LC. (2019). Impacts du prophage phi027 dans la biologie et la virulence de la souche épidémique Clostridioides difficile ribotype R027. Annual scientific retreat of the Inflammation & Pain research axis of the CHUS research center. Sherbrooke, Canada
  • Fortier LC. (2019). Phage-host interactions in Clostridioides difficile. Invited speaker for seminar series at Texas A&M, Department of Biology. Texas, United States of America
  • Fortier LC. (2019). Phage-host interactions in the human pathogen Clostridium difficile. Phage Fest - 10th anniversary William & Mary University, Department of Biology, Integrated Science Center. Williamsburg, United States of America
  • Fortier LC. (2018). C. difficile phages. 6th International Clostridium difficile symposium (ICDS). Bled, Slovenia
  • Fortier LC. (2018). Clostridium difficile et ses bactériophages. Invited speaker at Université Laval. Québec, Canada
  • Fortier LC. (2017). Interactions phages-hôte chez Clostridium difficile. Université Laval - Conférence invitée. Québec, Canada
  • Fortier LC. (2016). Interactions phages-hôte chez la bactérie pathogène Clostridium difficile. Conferences of the department of Immunology of the faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada
  • Fortier LC. (2016). La prescription des phages. French conference in medicine of Moncton. Moncton, Canada
  • Fortier LC. (2015). Le développement d'un nouvel antibiotique: de l'idée à la clinique. CursUS-Santé. Sherbrooke, Canada
  • Fortier LC. (2015). Phage-host interactions in Clostridium difficile. Invited speaker at the Institut Pasteur in Paris, France. Paris, France
  • *Sekulovic O, *Ospina Bedoya M, Fairweather N, Fortier LC. (2015). The phase-variable cell wall protein CwpV confers phage resistance to Clostridium difficile. *This abstract was selected for an oral presentation by the review committee. 5th ICDS meeting. Bled, Slovenia
  • Fortier LC, Déziel E, Weiss K, Behr M. (2014). "Les superbactéries, doit-on s'en préoccuper?" Superbugs, should we be preoccupied? I was invited as a microbiology expert (along with 3 other microbiologists) to discuss this topic with the public. Les grands rendez-vous scientifiques du Musée de l'Institut Armand-Frapier. Laval, Canada
  • *Sekulovic O, Fortier LC. (2014). A first glance at phage-host interactions in Clostridium difficile. * This abstract was selected for an oral presentation by the review committee, and won the Gisela Mosig prize for best abstract. General meeting of the American Society for Microbiology (ASM). Boston, United States of America
  • Fortier LC. (2014). Développement d'une plateforme pour l'étude du microbiote intestinal. Technological conferences of the research axis in inflammation and pain of the CHUS research center. Sherbrooke, Canada
  • Fortier LC. (2014). Impact des antibiotiques sur la susceptibilité aux infections à Clostridium difficile: une approche intégrative. 56e réunion annuelle du Club de Recherche Clinique du Québec. Mont Gabriel, Canada
  • Lafontaine DA, Marsault E, Malouin F, Fortier LC. (2014). The guanine riboswitch as a target for the treatment of C. difficile and S. aureus infections. Second presentation in front of potential investors (Amorchem, Neomed and MSBiV). Montréal, Canada
  • Bordeleau E, Purcell E, Lafontaine DA, Fortier LC, Tamayo R, Burrus V. (2013). Cyclic-di-GMP riboswitch-controlled type IV pili-mediated aggregation in Clostridium difficile. 8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia – ClosPath. Palm Cove, Australia
  • Fortier LC. (2013). Impact des antibiotiques sur la susceptibilité aux infections à Clostridium difficile: une approche integrative. First annual meeting of the Research Center on Inflammation and Cancer of the Université de Sherbrooke (CRICUS). Sherbrooke, Canada
  • Fortier LC. (2013). Pathogenèse des infections à Clostridium difficile et développement de nouveaux antibiotiques. Annual research forum of the faculty of medicine of the Université de Sherbrooke. Magog, Canada
  • Fortier LC. (2013). Phage-host interactions in the human pathogen Clostridium difficile. Seminars series at Memorial University. St-John's, Canada
  • Lafontaine DA, Marsault E, Malouin F, Fortier LC. (2013). The guanine riboswitch as a target for the treatment of C. difficile and S. aureus infections. First presentation in front of potential investors (Amorchem, Neomed and MSBiV). Montréal, Canada
  • Fortier LC. (2012). Genetic diversity of Clostridium difficile and novel therapeutic strategies. Invited speaker at ViroPharma Inc. Exton, United States of America
  • Fortier LC. (2012). Pathogenesis of Clostridium difficile infections and novel therapeutic strategies. Invited speaker at AvidBiotics Inc. South San Francisco, United States of America
  • Fortier LC. (2012). Pathogénèse des infections à Clostridium difficile. Conférences en microbiologie et en biotechnologie. Sherbrooke, Canada
  • (2011). Pathogenesis of Clostridium difficile infections and development of novel antimicrobial agents. Invited speaker for the annual CIHR Infection and Immunity consulting committee. Sherbrooke, Canada
  • Garneau JR, Valiquette L, Fortier LC. (2011). Sub-inhibitory concentrations of tigecycline inhibit sporulation of Clostridium difficile in vitro. 7th International Conference on the Molecular Biology and Pathogenesis of the Clostridia – ClosPath. Aymes, United States of America
  • Sirard S, Valiquette L, Fortier LC. (2010). Peut-on prédire la sévérité des infections à C. difficile (ICD) en se basant sur l’analyse génotypique et phénotypique des souches bactériennes?. Annual Meeting of the Association des Médecins Microbiologistes Infectiologues du Québec (AMMIQ-JAFA). Québec, Canada
  • Fortier LC, Sekulovic O, Meessen-Pinard M. (2010). The multiple facets of bacteriophages and their role in the diversity and virulence of C. difficile. 3rd International Clostridium difficile symposium. Bled, Slovenia
  • Mulhbacher J, Brouillette E, Malouin F, Fortier LC, Lafontaine DA. (2009). Guanine riboswitch as a target for new antibiotics family. Invited seminar at the faculty of medicine of the U. of Montreal. Montreal, Canada
  • Sekulovic O, Fortier LC. (2009). Impact des prophages sur la biologie de Clostridium difficile. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada
  • Sirard S, Valiquette L, Fortier LC. (2009). Infections à C. difficile: quand C. difficile, ce n’est jamais simple!. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada
  • Mulhbacher J, Fortier LC, Malouin F, Lafontaine DA. (2009). Novel antibioswitches as selective inhibitors of guanine-related metabolic pathways. 10th annual Eastern Ribo-club Opening Session. Magog, Canada
  • Sekulovic O, Meessen-Pinard M, Fortier LC. (2009). Prophage-enhanced toxin production in Clostridium difficile NAP1/027 lysogens. "This abstract was selected for a slide presentation by the review committee". 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, United States of America
  • Mulhbacher J, Fortier LC, Malouin F, Lafontaine DA. (2009). Riboswitch guanine: nouvelle cible pour les antibioswitches. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada
  • (2009). Rôle des bactériophages dans l’évolution et la virulence de Clostridium difficile. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel. Sherbrooke, Canada
  • Mulhbacher J, Heppell B, Moisan H, Malouin F, Fortier LC, Lafontaine DA. (2008). Guanine riboswitch inhibitors as promising new antibiotics family against S. aureus and C. difficile. 10th annual Ontario-Québec Biotechnology meeting. Sherbrooke, Canada
  • Mulhbacher J, Heppell B, Moisan H, Malouin F, Fortier LC, Lafontaine DA. (2008). Guanine riboswitch inhibitors as promising new antibiotics family against S. aureus and C. difficile. Conferences of the Ribo-club. Magog, Canada
  • Mulhbacher J, Heppell B, Moisan H, Malouin F, Fortier LC, Lafontaine DA. (2008). Guanine riboswitch inhibitors as promising new antibiotics family against S. aureus and C. difficile. RNA meeting. Berlin, Germany
  • Fortier LC. (2008). Potential of phage therapy to fight Clostridium difficile infections. Eliava-2008: Phage biology, ecology and therapy meeting. Tbilisi, Georgia
  • Mauler S, Fortier LC. (2008). Potentiel thérapeutique des endolysines pour prévenir ou traiter les infections à Clostridium difficile. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-Le Bel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada